Sarepta Therapeutics (SRPT) Misses Q1 EPS by 15c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.15), $0.15 worse than the analyst estimate of ($1.00).

Sarepta said its pre-NDA meeting with the FDA remains calendared for second quarter 2015.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Worried the AI trade has gone too far? Evercore likes these 4 stocks
• MP Materials seen largely insulated after China export-control move